Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05664633
Other study ID # 2107367192
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 2023
Est. completion date June 2024

Study information

Verified date July 2023
Source West Virginia University
Contact Omar Duenas Garcia, MD
Phone 855-WVU-CARE
Email omar.duenasgarcia@hsc.wvu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Investigator will perform a single-institution randomized double-blinded controlled trial comparing intraoperative Sugammadex vs. standard dose of glycopyrrolate/neostigmine combination for participants undergoing a total vaginal hysterectomy with or without pelvic organ prolapse procedures under general endotracheal anesthesia.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - female patients undergoing a vaginal hysterectomy with the indications of pelvic organ prolapse or abnormal uterine bleeding Exclusion Criteria: - Patients who are already known to have voiding dysfunction - Patients who have a contraindication or intolerance to any of the drugs used in the study - Has a medical condition or surgical procedure that precludes reversal of neuromuscular block at the end of surgery. - Has a neuromuscular disorder(s) that may affect neuromuscular block and/or trial assessments. - Is dialysis-dependent or has severe renal insufficiency, defined as estimated creatinine clearance of <30 mL/min. - Has or is suspected of having a personal history or family history (parents, grandparents, or siblings) of malignant hyperthermia. - Has or is suspected of having an allergy (e.g., hypersensitivity and/or anaphylactic reaction) to study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia. - Has received or is planned to receive toremifene within 24 hours before or within 24 hours after study medication administration. - Has any condition that would contraindicate the administration of study medication. - Is pregnant, is attempting to become pregnant, or is lactating. - Is currently participating in or has participated in an interventional clinical trial (including any other current or ongoing trial with a sugammadex treatment arm) with an investigational compound or device within 30 days of signing the informed consent form of this current trial. - Male patients - Patients undergoing a conventional laparoscopic or robotic approach - Patients having a midurethral sling in addition to the vaginal hysterectomy - Patients declining to participate in the study - Patients allergic to any of the drugs used in the study (sugammadex, neostigmine and/or glycopyrrolate)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sugammadex
Sugammadex or G/N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist. The surgeon will typically do this at the time of putting the closing sutures.

Locations

Country Name City State
United States West Virginia University Hospitals Morgantown West Virginia

Sponsors (1)

Lead Sponsor Collaborator
West Virginia University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Void Test (Pass) Number of patients that Pass the Void Test. Once the patients are oriented and before leaving PACU, their bladder will be backfilled with 300 ccs of normal saline or at capacity. Then 30 minutes will be given to void. The voided volume will be measured using a toilet hat, and the post-void residual will then be measured using a bladder scanner. Up to 4 hours postop
Primary Void Test (Fail) Number of patients that Fail the Void Test. Once the patients are oriented and before leaving PACU, their bladder will be backfilled with 300 ccs of normal saline or at capacity. Then 30 minutes will be given to void. If the patients are unable to void or if the post-void residual is > than 100 ml by bladder scanner, then it will be considered that those patients failed the voiding trial Up to 4 hours post-op
See also
  Status Clinical Trial Phase
Completed NCT03341819 - Comparative Study Between Retained and Non-retained Urinary Catheter in Total Knee Arthorplasty With Epidural Anesthesia N/A
Completed NCT05428020 - RCT Foley Catheter Study for Elective TJA N/A
Completed NCT05969145 - The Effect of Hot-Cold Application to the Bladder After Orthopedic Surgery on Postoperative Urinary Retention N/A
Completed NCT02133768 - Routine Bladder Catheterisation Through Fast-track Hip and Knee Replacement - What Are the Consequences? N/A
Terminated NCT01568918 - Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery Phase 3
Completed NCT05898919 - Acupuncture for Postoperative Urinary Retention After Hemorrhoidectomy: a Randomized Controlled Trial Phase 2
Completed NCT02958878 - Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Phase 4
Completed NCT02996968 - Self-discontinuation of a Transurethral Catheter N/A
Withdrawn NCT03937531 - Void Trials After Two Voiding Trials (TVT) N/A
Terminated NCT02518971 - Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients Phase 3
Recruiting NCT05276804 - The POUR (Postoperative Urinary Retention) Study Phase 3
Not yet recruiting NCT06258785 - Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension Phase 3